MX2020012540A - Uso de inhibidor de cdk4/6 en combinacion con inhibidor del egfr en la preparacion de medicamento para tratar enfermedades tumorales. - Google Patents

Uso de inhibidor de cdk4/6 en combinacion con inhibidor del egfr en la preparacion de medicamento para tratar enfermedades tumorales.

Info

Publication number
MX2020012540A
MX2020012540A MX2020012540A MX2020012540A MX2020012540A MX 2020012540 A MX2020012540 A MX 2020012540A MX 2020012540 A MX2020012540 A MX 2020012540A MX 2020012540 A MX2020012540 A MX 2020012540A MX 2020012540 A MX2020012540 A MX 2020012540A
Authority
MX
Mexico
Prior art keywords
inhibitor
cdk4
medicament
preparation
combination
Prior art date
Application number
MX2020012540A
Other languages
English (en)
Inventor
Lianshan Zhang
Lei Zhang
Changyong Yang
Cheng Liao
Original Assignee
Jiangsu Hengrui Medicine Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hengrui Medicine Co filed Critical Jiangsu Hengrui Medicine Co
Publication of MX2020012540A publication Critical patent/MX2020012540A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

Se provee en la presente invención el uso de un inhibidor de CDK4/6 en combinación con un inhibidor del EGFR en la preparación de un medicamento para tratar enfermedades tumorales; en particular, se provee en la invención el uso de un inhibidor de las cinasas 4 y 6 dependientes de ciclina (CDK4/6i) en combinación con un inhibidor del receptor del factor de crecimiento epidérmico humano (EGFRi) en la preparación de un medicamento para prevenir o tratar enfermedades tumorales.
MX2020012540A 2018-05-23 2019-05-22 Uso de inhibidor de cdk4/6 en combinacion con inhibidor del egfr en la preparacion de medicamento para tratar enfermedades tumorales. MX2020012540A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN201810499596 2018-05-23
CN201811086544 2018-09-18
CN201811182296 2018-10-11
PCT/CN2019/087945 WO2019223716A1 (zh) 2018-05-23 2019-05-22 Cdk4/6抑制剂与egfr抑制剂联合在制备治疗肿瘤疾病的药物中的用途

Publications (1)

Publication Number Publication Date
MX2020012540A true MX2020012540A (es) 2021-02-16

Family

ID=68616085

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020012540A MX2020012540A (es) 2018-05-23 2019-05-22 Uso de inhibidor de cdk4/6 en combinacion con inhibidor del egfr en la preparacion de medicamento para tratar enfermedades tumorales.

Country Status (9)

Country Link
US (1) US20210196719A1 (es)
EP (1) EP3811946A4 (es)
JP (1) JP2021525244A (es)
KR (1) KR20210013155A (es)
CN (1) CN111818925B (es)
CA (1) CA3100867A1 (es)
MX (1) MX2020012540A (es)
TW (1) TWI762784B (es)
WO (1) WO2019223716A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202211923A (zh) * 2020-07-27 2022-04-01 美商光譜製藥公司 波奇替尼(poziotinib)於非小細胞肺癌之治療
CN112168828A (zh) * 2020-11-10 2021-01-05 南京医科大学 一种egfr与cdk4/6小分子靶向药组合物及其应用
CN114748479B (zh) * 2021-01-08 2023-10-20 轩竹生物科技股份有限公司 一种预防和/或治疗癌症的药物组合物
WO2022253222A1 (zh) * 2021-06-04 2022-12-08 洪明奇 医药组合物治疗肺癌的用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0706633D0 (en) * 2007-04-04 2007-05-16 Cyclacel Ltd Combination
TW201242597A (en) * 2011-03-14 2012-11-01 Piramal Life Sciences Ltd A synergistic pharmaceutical combination for the treatment of pancreatic cancer
US9321749B1 (en) * 2012-07-25 2016-04-26 Globavir Biosciences, Inc. Heterocyclic compounds and uses thereof
WO2014183520A1 (zh) * 2013-05-17 2014-11-20 上海恒瑞医药有限公司 吡啶并嘧啶类衍生物、其制备方法及其在医药上的应用
CN111187221B (zh) * 2014-10-11 2023-09-26 上海翰森生物医药科技有限公司 Egfr抑制剂及其制备和应用
RS59782B1 (sr) * 2015-02-03 2020-02-28 Jiangsu hengrui medicine co ltd Hidroksietil sulfonat od ciklina zavisnog inhibitora kinaze proteina, njegov kristalni oblik, i postupak za njegovo dobijanje
ES2761885T3 (es) * 2015-08-28 2020-05-21 Novartis Ag Combinaciones farmacéuticas que comprenden (a) el inhibidor de la cinasa dependiente de ciclina 4/6 (CDK4/6) LEE011 (= ribociclib) y (b) el inhibidor del receptor del factor de crecimiento epidérmico (EGFR) erlotinib, para el tratamiento o la prevención del cáncer
WO2017160568A1 (en) 2016-03-16 2017-09-21 Eli Lilly And Company Combination therapy comprising the cdk4/6 inhibitor necitumumab and the egfr inhibitor abemaciclib for use in treating cancer
RU2733412C2 (ru) 2016-03-22 2020-10-01 Цзянсу Хансох Фармасьютикал Груп Ко., Лтд. Поликристаллическая форма свободного основания или соли присоединения кислоты ингибитора egfr, способ её получения и применение
WO2017193141A1 (en) * 2016-05-06 2017-11-09 Siyuan Zhang Prognosis biomarkers and anti-tumor compositions of targeted therapeutic treatments for triple negative breast cancer
CN107652284B (zh) * 2017-09-30 2020-01-31 武汉九州钰民医药科技有限公司 用于治疗增殖性疾病的cdk抑制剂

Also Published As

Publication number Publication date
TW202002964A (zh) 2020-01-16
CN111818925A (zh) 2020-10-23
CA3100867A1 (en) 2019-11-28
JP2021525244A (ja) 2021-09-24
US20210196719A1 (en) 2021-07-01
WO2019223716A1 (zh) 2019-11-28
CN111818925B (zh) 2023-12-12
KR20210013155A (ko) 2021-02-03
EP3811946A4 (en) 2022-02-09
TWI762784B (zh) 2022-05-01
EP3811946A1 (en) 2021-04-28

Similar Documents

Publication Publication Date Title
MX2020012540A (es) Uso de inhibidor de cdk4/6 en combinacion con inhibidor del egfr en la preparacion de medicamento para tratar enfermedades tumorales.
MX2020008559A (es) Compuestos heterocíclicos como inhibidores de la quinasa.
PH12016501394A1 (en) Compounds for treating patients with ros1 mutant cancer cells
MX2020012165A (es) Derivados de bencimidazol como inhibidores de tirosina cinasa erbb para el tratamiento del cancer.
MX2020009773A (es) Terapia de combinacion.
WO2016070051A3 (en) Combination therapy for treatment of disease
MX2017014338A (es) Seleccion dirigida de pacientes para el tratamiento con derivados de cortistatina.
EP2576549A4 (en) Bicyclic Heteroarylkinase Inhibitors and Methods of Use
BR112018016554A2 (pt) composto de uréia, método de preparação deste e uso médico deste
MX2023005747A (es) Inhibidores de gcn2 y perk quinasas y metodos de uso de los mismos.
PH12017500724A1 (en) Carbazole derivatives
BR112015026247A2 (pt) métodos para o tratamento de câncer com o uso de terapia combinada com inibidor de cinase tor
WO2020140054A8 (en) Cyclin-dependent kinase inhibitors
JOP20190234B1 (ar) مركب كبير الحلقات واستخداماته
MX2019015207A (es) Compuestos para tratar el cancer de ovario.
WO2017040666A3 (en) Combination therapy for treatment of disease
NZ756264A (en) Treatment of brain cancer
MX2021000726A (es) Terapia combinada de gen de activacion de linfocitos 3(lag-3) para el tratamiento del cancer.
JOP20220107A1 (ar) مثبطات egfr تفارغية وطرق استخدامها
EP4051282A4 (en) METHOD FOR TREATING CANCER IN BIOMARRKER-IDENTIFIED PATIENTS USING CYCLIN-DEPENDENT KINASE 7 (CDK7) INHIBITORS
EP4081527A4 (en) COMBINATION OF A CYCLIN-DEPENDENT KINASE-7 INHIBITOR AND IMMUNOTHERAPY FOR THE TREATMENT OF CANCER
MX2020008395A (es) Osimertinib para su uso en el tratamiento de cáncer de pulmón de células no pequeñas.
PH12021551276A1 (en) Combination therapy for the treatment of cancer
EP3991749A3 (en) A therapeutic agent for a tumor comprising an ido inhibitor administered in combination with an antibody
MX2019010981A (es) Terapias de combinacion para el tratamiento de cancer de mama.